Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nijenrode. Before starting up Aglaia, he was involved in the founding, restructuring and funding of multiple technology-driven companies. In 1995, he founded Entity Holding B.V., a venture company focusing on early-stage companies. Karl serves at the board of a number of life sciences companies.
Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures